2019冠状病毒病患者的抗凝治疗:迫切需要提高认识

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

European Cardiology Review Pub Date : 2020-08-07 eCollection Date: 2020-02-01 DOI:10.15420/ecr.2020.24

Maki Komiyama, Koji Hasegawa

{"title":"2019冠状病毒病患者的抗凝治疗:迫切需要提高认识","authors":"Maki Komiyama, Koji Hasegawa","doi":"10.15420/ecr.2020.24","DOIUrl":null,"url":null,"abstract":"Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 receptor, which is abundantly expressed in vascular endothelial cells and damages these cells. Besides pneumonia-induced respiratory failure, thrombotic cardiovascular complications are increasingly emerging as a major COVID-19 symptom. Multiple retrospective studies have strongly suggested that anticoagulant therapy improves the prognosis of people with COVID-19. However, validation of the safety and effectiveness of anticoagulant therapy for COVID-19 and greater awareness of this clinical therapeutic option are urgently needed.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"15 ","pages":"e58"},"PeriodicalIF":3.2000,"publicationDate":"2020-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/4c/ecr-15-e58.PMC7479536.pdf","citationCount":"12","resultStr":"{\"title\":\"Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness.\",\"authors\":\"Maki Komiyama, Koji Hasegawa\",\"doi\":\"10.15420/ecr.2020.24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 receptor, which is abundantly expressed in vascular endothelial cells and damages these cells. Besides pneumonia-induced respiratory failure, thrombotic cardiovascular complications are increasingly emerging as a major COVID-19 symptom. Multiple retrospective studies have strongly suggested that anticoagulant therapy improves the prognosis of people with COVID-19. However, validation of the safety and effectiveness of anticoagulant therapy for COVID-19 and greater awareness of this clinical therapeutic option are urgently needed.\",\"PeriodicalId\":45957,\"journal\":{\"name\":\"European Cardiology Review\",\"volume\":\"15 \",\"pages\":\"e58\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2020-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/4c/ecr-15-e58.PMC7479536.pdf\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Cardiology Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15420/ecr.2020.24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/2/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Cardiology Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/ecr.2020.24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/2/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 12

摘要

由严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)引起的冠状病毒病2019 (COVID-19)已成为全球大流行。SARS-CoV-2与血管紧张素转换酶2受体结合，血管紧张素转换酶2受体在血管内皮细胞中大量表达，并损害这些细胞。除了肺炎引起的呼吸衰竭外，血栓性心血管并发症越来越多地成为COVID-19的主要症状。多项回顾性研究强烈表明，抗凝治疗可改善COVID-19患者的预后。然而，迫切需要验证COVID-19抗凝治疗的安全性和有效性，并提高对这一临床治疗选择的认识。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness.

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 receptor, which is abundantly expressed in vascular endothelial cells and damages these cells. Besides pneumonia-induced respiratory failure, thrombotic cardiovascular complications are increasingly emerging as a major COVID-19 symptom. Multiple retrospective studies have strongly suggested that anticoagulant therapy improves the prognosis of people with COVID-19. However, validation of the safety and effectiveness of anticoagulant therapy for COVID-19 and greater awareness of this clinical therapeutic option are urgently needed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Cardiology Review CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

12 weeks